Study reveals how transcription factor EVI1 contributes to cancer development and tumor invasion

June 20, 2012

Since its discovery close to 25 years ago, the EVI1 gene has emerged as a major player in many different types of cancer, including leukemia and tumors of the breast, prostate and colon, among other organs. In the US, for example, there is a company called NanoOncology that was founded to develop drugs for blocking this oncogene. Yet, despite all the interest in EVI1, very few of the gene’s downstream targets are known.

Emilie Bard-Chapeau at the A*STAR Institute of Molecular and Cell Biology and co-workers1 have now used a systems biology approach to identify a slew of tumor-associated genes that are controlled by EVI1. The discovery could lead to new therapeutic strategies to combat various forms of cancer.

The EVI1 gene — short for ‘ecotropic viral integration site 1’ — encodes a zinc-finger transcription factor with two distinct DNA binding domains. When overexpressed, this leads to aggressive forms of cancer and poor patient survival. To better understand the biochemical functions of EVI1, Bard-Chapeau and co-workers searched for gene promoters and cooperating that are actively bound by EVI1 in human ovarian cancer and chronic myeloid cell lines.

Systems biology uses a palette of analytical and computational techniques to study the complex interactions in biological systems. Using microarrays, ChIP-sequencing and immunoprecipitation assays, the researchers found that the two different zinc-finger domains of EVI1 activate unique sets of target genes, many of which are involved in cell adhesion, proliferation, colony formation and other aspects of growth.

Notably, the researchers documented a strong association between EVI1 and FOS — the latter being one of the main components of the activator protein 1 (AP1) transcription factor complex that is known to drive tumorigenesis. Experiments in cell lines showed that EVI1 and FOS interact to co-regulate many hallmarks of cancer, and follow-up analyses in late-stage ovarian cancers taken from patients revealed an enrichment in expressed genes linked to both EVI1 and AP1. Taken together, the findings suggest that EVI1 expression might serve to fully elicit FOS oncogenic potential through a feed-forward regulatory loop that drives abnormal tissue changes.

“Our study has provided new mechanistic insights into the regulatory mechanism of EVI1, and revealed how EVI1 can function as a central player in many types of late-stage cancers,” says Bard-Chapeau. “Disruption of the interaction between EVI1 and FOS may be a very interesting way to prevent cancer progression.”

Explore further: New approach to link genome-wide association signals to biological function

More information: Bard-Chapeau, E. A. et al. Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors. Proceedings of the National Academy of Sciences 109, 2168–2173 (2012).

Related Stories

New lung cancer gene found

July 19, 2011

A major challenge for cancer biologists is figuring out which among the hundreds of genetic mutations found in a cancer cell are most important for driving the cancer’s spread.

Recommended for you

Malaria vaccine provides hope for a general cure for cancer

October 13, 2015

The hunt for a vaccine against malaria in pregnant women has provided an unexpected side benefit for Danish researchers, namely what appears to be an effective weapon against cancer. The scientists behind the vaccine aim ...

Breast cancer drug beats superbug

October 13, 2015

Researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have found that the breast cancer drug tamoxifen gives white blood cells a boost, better enabling ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.